Real-world costs of chronic lymphocytic leukaemia in the Netherlands

K. M. Holtzer-Goor; C. A M Bouwmans-Frijters; M. R. Schaafsma; O. de Weerdt; P. Joosten; E. F M Posthuma; S. Wittebol; P. C. Huijgens; E. J M Mattijssen; G. Vreugdenhil; H. Visser; W. G. Peters; Z. Erjavec; P. W. Wijermans; S. M G J Daenen; K. G. van der Hem; M. H J van Oers; C. A Uyl de Groot

doi:10.1016/j.leukres.2013.10.029

Real-world costs of chronic lymphocytic leukaemia in the Netherlands

K. M. Holtzer-Goor^*, C. A M Bouwmans-Frijters, M. R. Schaafsma, O. de Weerdt, P. Joosten, E. F M Posthuma, S. Wittebol, P. C. Huijgens, E. J M Mattijssen, G. Vreugdenhil, H. Visser, W. G. Peters, Z. Erjavec, P. W. Wijermans, S. M G J Daenen, K. G. van der Hem, M. H J van Oers, C. A Uyl de Groot

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) received >= 1 treatment lines during an average follow-up time of 6.4 years. The average total costs per patient were (sic)41,417 ((sic)539 per month). The costs varied considerably between treatment groups and between treatment lines. Although patients were treated with expensive chemo(immuno-)therapy, the main cost driver was inpatient days for other reasons than administration of chemo(immuno-)therapy. (C) 2013 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	84-90
Number of pages	7
Journal	Leukemia Research
Volume	38
Issue number	1
DOIs	https://doi.org/10.1016/j.leukres.2013.10.029
Publication status	Published - Jan 2014

Keywords

Chronic lymphocytic leukaemia
Cost of illness
Costs
Observational study
Outcomes research
Real-world

Access to Document

10.1016/j.leukres.2013.10.029

http://www.mendeley.com/research/realworld-costs-chronic-lymphocytic-leukaemia-netherlands

Cite this

Holtzer-Goor, K. M., Bouwmans-Frijters, C. A. M., Schaafsma, M. R., de Weerdt, O., Joosten, P., Posthuma, E. F. M., Wittebol, S., Huijgens, P. C., Mattijssen, E. J. M., Vreugdenhil, G., Visser, H., Peters, W. G., Erjavec, Z., Wijermans, P. W., Daenen, S. M. G. J., van der Hem, K. G., van Oers, M. H. J., & Groot, C. A. U. D. (2014). Real-world costs of chronic lymphocytic leukaemia in the Netherlands. Leukemia Research, 38(1), 84-90. https://doi.org/10.1016/j.leukres.2013.10.029

@article{2f0d9be9f08e4189ac887a4f2fe7266b,

title = "Real-world costs of chronic lymphocytic leukaemia in the Netherlands",

abstract = "We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) received >= 1 treatment lines during an average follow-up time of 6.4 years. The average total costs per patient were (sic)41,417 ((sic)539 per month). The costs varied considerably between treatment groups and between treatment lines. Although patients were treated with expensive chemo(immuno-)therapy, the main cost driver was inpatient days for other reasons than administration of chemo(immuno-)therapy. (C) 2013 Elsevier Ltd. All rights reserved.",

keywords = "Chronic lymphocytic leukaemia, Cost of illness, Costs, Observational study, Outcomes research, Real-world",

author = "Holtzer-Goor, {K. M.} and Bouwmans-Frijters, {C. A M} and Schaafsma, {M. R.} and {de Weerdt}, O. and P. Joosten and Posthuma, {E. F M} and S. Wittebol and Huijgens, {P. C.} and Mattijssen, {E. J M} and G. Vreugdenhil and H. Visser and Peters, {W. G.} and Z. Erjavec and Wijermans, {P. W.} and Daenen, {S. M G J} and {van der Hem}, {K. G.} and {van Oers}, {M. H J} and Groot, {C. A Uyl de}",

note = "No ISBN available. ISSN is 0145-2126.",

year = "2014",

month = jan,

doi = "10.1016/j.leukres.2013.10.029",

language = "English",

volume = "38",

pages = "84--90",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "1",

}

Holtzer-Goor, KM, Bouwmans-Frijters, CAM, Schaafsma, MR, de Weerdt, O, Joosten, P, Posthuma, EFM, Wittebol, S, Huijgens, PC, Mattijssen, EJM, Vreugdenhil, G, Visser, H, Peters, WG, Erjavec, Z, Wijermans, PW, Daenen, SMGJ, van der Hem, KG, van Oers, MHJ & Groot, CAUD 2014, 'Real-world costs of chronic lymphocytic leukaemia in the Netherlands', Leukemia Research, vol. 38, no. 1, pp. 84-90. https://doi.org/10.1016/j.leukres.2013.10.029

TY - JOUR

T1 - Real-world costs of chronic lymphocytic leukaemia in the Netherlands

AU - Holtzer-Goor, K. M.

AU - Bouwmans-Frijters, C. A M

AU - Schaafsma, M. R.

AU - de Weerdt, O.

AU - Joosten, P.

AU - Posthuma, E. F M

AU - Wittebol, S.

AU - Huijgens, P. C.

AU - Mattijssen, E. J M

AU - Vreugdenhil, G.

AU - Visser, H.

AU - Peters, W. G.

AU - Erjavec, Z.

AU - Wijermans, P. W.

AU - Daenen, S. M G J

AU - van der Hem, K. G.

AU - van Oers, M. H J

AU - Groot, C. A Uyl de

N1 - No ISBN available. ISSN is 0145-2126.

PY - 2014/1

Y1 - 2014/1

N2 - We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) received >= 1 treatment lines during an average follow-up time of 6.4 years. The average total costs per patient were (sic)41,417 ((sic)539 per month). The costs varied considerably between treatment groups and between treatment lines. Although patients were treated with expensive chemo(immuno-)therapy, the main cost driver was inpatient days for other reasons than administration of chemo(immuno-)therapy. (C) 2013 Elsevier Ltd. All rights reserved.

AB - We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) received >= 1 treatment lines during an average follow-up time of 6.4 years. The average total costs per patient were (sic)41,417 ((sic)539 per month). The costs varied considerably between treatment groups and between treatment lines. Although patients were treated with expensive chemo(immuno-)therapy, the main cost driver was inpatient days for other reasons than administration of chemo(immuno-)therapy. (C) 2013 Elsevier Ltd. All rights reserved.

KW - Chronic lymphocytic leukaemia

KW - Cost of illness

KW - Costs

KW - Observational study

KW - Outcomes research

KW - Real-world

U2 - 10.1016/j.leukres.2013.10.029

DO - 10.1016/j.leukres.2013.10.029

M3 - Article

C2 - 24268350

SN - 0145-2126

VL - 38

SP - 84

EP - 90

JO - Leukemia Research

JF - Leukemia Research

IS - 1

ER -